Zacks Research Has Optimistic Outlook of HALO Q1 Earnings
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Investment analysts at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report released on Tuesday, April 29th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.88 per share for the quarter, up […]
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Investment analysts at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a report released on Tuesday, April 29th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will earn $0.88 per share for the quarter, up […]
